These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 3266532)

  • 1. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase.
    Palfreyman MG; McDonald IA; Fozard JR; Mely Y; Sleight AJ; Zreika M; Wagner J; Bey P; Lewis PJ
    J Neurochem; 1985 Dec; 45(6):1850-60. PubMed ID: 3840523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
    Zreika M; Fozard JR; Dudley MW; Bey P; McDonald IA; Palfreyman MG
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):243-54. PubMed ID: 2597310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.
    Fozard JR; Palfreyman MG; Robin M; Zreika M
    Br J Pharmacol; 1986 Jan; 87(1):257-64. PubMed ID: 3082400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acute effect of the bioprecursor of the selective brain MAO-A inhibitor, MDL 72392, on rat pineal melatonin biosynthesis.
    Oxenkrug GF; Requintina PJ; Yuwiler A; Palfreyman MG
    J Neural Transm Suppl; 1994; 41():377-9. PubMed ID: 7931254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B.
    Zreika M; McDonald IA; Bey P; Palfreyman MG
    J Neurochem; 1984 Aug; 43(2):448-54. PubMed ID: 6736960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase.
    Palfreyman MG; Mir AK; Kubina M; Middlemiss DN; Richards M; Tricklebank MD; Fozard JR
    Eur J Pharmacol; 1986 Oct; 130(1-2):73-89. PubMed ID: 3780861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
    Fozard JR; Zreika M; Robin M; Palfreyman MG
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):186-93. PubMed ID: 3937059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B.
    Kindt MV; Heikkila RE
    Life Sci; 1986 Apr; 38(16):1459-62. PubMed ID: 3084895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72.974A in normal volunteers.
    Hinze C; Harland D; Zreika M; Dulery B; Hardenberg J
    J Neural Transm Suppl; 1990; 32():203-9. PubMed ID: 2089092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction.
    Pickar D; Cohen RM; Jimerson DC; Lake CR; Murphy DL
    Psychopharmacology (Berl); 1981; 74(1):8-12. PubMed ID: 6791210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species.
    Yu PH; Zuo DM
    Biochem Pharmacol; 1992 Jan; 43(2):307-12. PubMed ID: 1739419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of monoamine oxidase within monoaminergic neurons in the rat brain by (E)-beta-fluoromethylene-m-tyrosine (MDL 72394).
    Fagervall I; Ross SB
    J Neurochem; 1989 Feb; 52(2):467-71. PubMed ID: 2521360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine.
    Hinze C; Kaschube M; Hardenberg J
    J Neural Transm Suppl; 1994; 41():371-5. PubMed ID: 7931253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.
    McDonald IA; Lacoste JM; Bey P; Palfreyman MG; Zreika M
    J Med Chem; 1985 Feb; 28(2):186-93. PubMed ID: 3968682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
    Gal S; Abassi ZA; Youdim MB
    Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vivo effects of (E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues.
    Elliott J; Callingham BA; Barrand MA
    J Pharm Pharmacol; 1989 Jan; 41(1):37-41. PubMed ID: 2565962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.